Follow-up: Tirzepatide's shorter half-life and its one practical consequence posts 121–138

That is a cleaner way of putting what I was circling around.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Post #122 is the version of this I will quote in future. One addition.

Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.

Adding the caveat now so it does not have to be extracted later.

Where I part company with post #122, and it is a narrow parting.

Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.

The literature is thinner on this than the confidence in the thread implies.

Narrowing post #122, because the general version has more than one answer.

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

The variance between people here is larger than the effect being discussed.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Written in the hope of being told what I have missed.

Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.

Not the whole picture, but the part of it I can speak to.

Post #126 answers the question as asked. The question underneath it is different.

Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.

If that is already documented somewhere, ignore me and link it.

This is the first time the answer has come with its own limits attached. Appreciated.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Gastrointestinal effects were comparable in character to the GLP-1 monoagonists across the programme. Individual reports here vary in both directions, which is what you would expect from a between-person difference rather than a between-drug one.

Someone should write this up properly, and it should probably not be me.

Right — I had this wrong and I am glad to have read it before it mattered.

The 2.5 mg starting dose is a tolerance step and not a therapeutic one. Judging efficacy at that dose is the single commonest reasoning error in this subcategory.